BioSpace News Archive

DiamiR announced it was selected by the National Institutes of Health as one of Small Business Innovation Research awardees to showcase its technology at the BIO 2019 International Convention held June 3 - 6 in Philadelphia, PA.

Kala Pharmaceuticals, Inc. announced that it will present at the Jefferies 2019 Healthcare Conference in New York, NY. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Thursday, June 6, 2019 at 2:30 p.m. ET.

Ocular Therapeutix, Inc. announced that it will present and host investor meetings at the following conferences

Study is first in the world to evaluate a transcatheter therapy designed to improve left ventricular function for heart failure patients with reduced ejection fraction

Healthe announced the public release of its Eyesafe® standards for managing blue light emissions and maintaining color performance for display and screen protection products.

SCYNEXIS, Inc. announced that the company has completed the nonclinical toxicology evaluations that are required by regulatory authorities, including the U.S. Food and Drug Administration (FDA), to support long-term administration in human clinical trials.

NeuroRx, a clinical stage biopharma company focused on development of drugs to target suicidal depression and PTSD, announced statistically significant final results from its Phase 2 STABIL-B study of NRX-101 versus lurasidone in patients with Severe Bipolar Depression and Acute Suicidal Ideation or Behavior (ASIB).

CollPlant announced financial results for the first quarter ended March 31, 2019 and provided an update on the Company’s business developments.

Metagenics, Inc., a health sciences company, announced the release of its new formula, Hemp Oil, an organic, broad-spectrum hemp extract.

REGENXBIO Inc. announced it completed dosing across all five cohorts in the Phase I/IIa clinical trial of RGX-314 for the treatment of wet age-related macular degeneration.